Lilly sees surging sales in contrast to obesity rival Novo

The guidance was a sharp contrast to rival Novo Nordisk A/S, which warned investors Tuesday that its sales could drop as much as 13% this year on intensifying price competition in the weight loss market

Source: Bloomberg

Continue reading...